Royalty Pharma plc RPRX
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 12, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
7 paragraphs in Risk Factors of the 10-K filed Feb 11, 2026 with nothing like them in the 10-K filed Feb 12, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
•our ability to generate increasing royalty receipts and to achieve attractive returns on our investments, including maintaining attractive internal rates of return and consistent returns on invested capital and returns on invested equity;
•we may not realize the anticipated benefits of the Internalization and we may be exposed to new risks and costs;
We may not realize the anticipated benefits of the Internalization or we may be exposed to new risks and costs.
• analyst or media reports or other adverse publicity about us, our industry or related sectors;
Whether we are a PFIC is a complex legal and factual question. We regularly review whether we expect to be classified as a PFIC in the current year or are likely to be classified as a PFIC in a future year. We may reach the conclusion in future years that we should not be classified as a PFIC.
Beginning in the second quarter of 2025, we did not receive from Vertex the full amount of royalty receipts on Alyftrek net sales to which we believe that we are contractually entitled. Accordingly, we commenced the dispute resolution procedures contemplated by the agreements relating to our royalties on Vertex’s cystic fibrosis products. Any amounts receivable by us, if any, in connection with this dispute will be recognized only upon the resolution of the matter in our favor.
The resolution of, or increase in the reserves taken in connection with, one or more of these matters could adversely affect our business, financial condition or results of operations. In addition, adverse publicity or market reaction arising from legal claims or proceedings could harm our reputation, relationships with counterparties or ability to pursue future business opportunities.
Paragraphs in the 10-Q filed Nov 4, 2026 that were not in the one before
New in the latest 10-Q
19 paragraphs in the 10-Q filed Nov 4, 2026 with nothing like them in the 10-Q filed Aug 5, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Financial statements and notes
Distributions to legacy non-controlling interests - Portfolio Receipts (257,036) (275,752)
Read in the 10-Q
In 2026 and 2025, we entered into the following R&D funding agreements under which we provide funding over time (in thousands):
Read in the 10-Q
In connection with the Internalization, RP Holdings and RP Manager were each joined as a borrower under RPM’s then existing $ 380 million term loan with Bank of America, N.A., and RPM was released as a borrower upon closing of the Internalization. In July 2026, we repaid the $ 380 million term loan.
Read in the 10-Q
Non-cash investing and financing activities are summarized below (in thousands):
Read in the 10-Q
• Rasonque. In October 2026, Revolution Medicines announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion of Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
Read in the 10-Q
Show the other 14
In October 2026, we funded the required first $250 million tranche of the up to $750 million senior secured term loans to Revolution Medicines. Additionally, Revolution Medicines elected not to exercise its option for the third royalty funding tranche (which was up to $250 million). Up to an additional $500 million may be available at Revolution Medicines’ option under each of the senior secured term loan and royalty funding agreement, based on the achievement of certain milestones.
Read in the 10-Q
In August 2026, Revolution Medicines announced that the FDA approved Rasonque for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Read in the 10-Q
• Niktimvo. In October 2026, Syndax Pharmaceuticals (“Syndax”) announced that the Phase 2 MAXPIRe trial of Niktimvo in idiopathic pulmonary fibrosis (“IPF”) did not meet its primary endpoint. Syndax does not plan to move forward with further development in IPF. The results do not affect ongoing trials of Niktimvo in other indications.
Read in the 10-Q
• Weltruza. In October 2026, Teva Pharmaceuticals (“Teva”) announced that the FDA approved Weltruza (formerly known as TEV-’749) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable for the treatment of schizophrenia in adults. We agreed to convert $50 million of approval milestone into additional royalties, which will cease after we receive a 1.2x return. In total, we expect to receive (1) a $50 million approval milestone of the original amount payable in equal installments over four years, (2) an incremental double-digit royalty with total receipts capped at $60 million and (3) a separate low-single-digit royalty.
Read in the 10-Q
• Imdelltra. In September 2026, Amgen announced positive results from the Phase 3 DeLLphi-305 study of Imdelltra in combination with Imfinzi as first-line maintenance treatment for extensive-stage small cell lung cancer. The study met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival, and also met secondary endpoints of progression-free survival and objective response rate.
Read in the 10-Q
• Mimrylo. In August 2026, Takeda announced that the FDA approved Mimrylo (formerly known as rusfertide), a hepcidin mimetic peptide, for the treatment of erythrocytosis in adults with polycythemia vera.
Read in the 10-Q
• Pelabresib. In October 2026, Novartis announced that the regulatory submission for pelabresib in myelofibrosis was completed in the European Union, based on the positive Phase 3 MANIFEST-2 study.
Read in the 10-Q
• Trontinemab. In September 2026, Roche announced that Phase 3 studies of trontinemab in early Alzheimer’s disease have fully enrolled, with data expected in the first half of 2028.
Read in the 10-Q
• Deucrictibant. In September 2026, Pharvaris announced positive results from the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release for the prevention of hereditary angioedema (“HAE”) attacks. The primary endpoint and all secondary efficacy endpoints were met with statistical significance.
Read in the 10-Q
• Pelacarsen. In September 2026, Novartis announced that the Phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events in the overall study population compared to placebo. In the third quarter of 2026, we recorded a non-cash impairment charge of $150.4 million related to pelacarsen.
Read in the 10-Q
• TEV-’408. In September 2026, Teva announced positive topline results from an ongoing Phase 2a study of TEV-’408, an anti-IL-15 antibody, in adults with celiac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8, and was well tolerated, with no safety signals observed to date.
Read in the 10-Q
• In September 2026, we acquired a royalty interest in Zoryve from AstraZeneca for $100 million upfront. Zoryve, marketed by Arcutis Biotherapeutics, is a topical phosphodiesterase type 4 inhibitor approved for atopic dermatitis, seborrheic dermatitis and plaque psoriasis.
Read in the 10-Q
• In August 2026, we acquired a royalty interest in Mimrylo, formerly known as rusfertide, from Zealand Pharma for $100 million, consisting of $50 million paid upfront and the remaining $50 million payable on the first anniversary of the closing. Marketed by Takeda, Mimrylo is a first-in-class therapy approved for polycythemia vera, a rare and chronic blood disorder.
Read in the 10-Q
In connection with the Internalization, RP Holdings and RP Manager were each joined as a borrower under RPM’s then existing $380 million term loan with Bank of America, N.A., and RPM was released as a borrower upon closing of the Internalization. In July 2026, we repaid the $380 million term loan.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 4, 2026 against Item 1A of the 10-K filed Feb 11, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
Show the other 1
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 11, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 12, 2025
Where each one is used
- internal rates: •our ability to generate increasing royalty receipts and to achieve attractive returns on our investments, including maintaining attractive internal rates of return and consistent returns on invested capital and returns on invested equity;
- invested capital: •our ability to generate increasing royalty receipts and to achieve attractive returns on our investments, including maintaining attractive internal rates of return and consistent returns on invested capital and returns on invested equity;
- invested equity: •our ability to generate increasing royalty receipts and to achieve attractive returns on our investments, including maintaining attractive internal rates of return and consistent returns on invested capital and returns on invested equity;
- new risks: •we may not realize the anticipated benefits of the Internalization and we may be exposed to new risks and costs;
- reimbursement rates: Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, delays or failures in obtaining marketing approval in one or more jurisdictions or for additional product indications, lack of...
- agreements governing: Our level of indebtedness could limit our ability to respond to changing business conditions. The agreements governing our borrowings may impose operating and financial restrictions which could affect the number and size of the royalties that we may pursue. Therefore, no assurance can be given that we will be able...
- key professionals: Our key professionals have relationships with participants in the biopharmaceutical industry, financial institutions and other professionals, which we rely upon to source potential asset acquisition opportunities. If our key professionals fail to maintain such relationships, or to develop new relationships with...
- term loan: As of December 31, 2025, our total principal amount of our senior unsecured notes and borrowings under our term loan was $9.2 billion. In addition to this indebtedness, we have up to $1.8 billion of available revolving commitments under our Revolving Credit Facility (as defined below). Furthermore, on August 4,...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
33 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RPRX/export.csv") into a cell.